DHHC7 palmitoylates KRAS4A and promotes mutant KRAS-driven pancreatic cancers

This study identifies DHHC7 as a critical palmitoyl transferase that modifies KRAS4A at Cys180 to drive its membrane nanoclustering and downstream RAF signaling, thereby promoting pancreatic cancer growth and highlighting DHHC7 as a promising therapeutic target for KRAS-mutant cancers.

The Gist

The Big Picture: A "Switch" for Cancer Growth

Imagine your body is a bustling city. The KRAS protein is like a traffic controller at a major intersection. Its job is to tell cells when to grow and divide. Usually, it's very careful and follows the rules. But in many cancers (especially pancreatic cancer), the KRAS controller gets a "glitch" in its programming. It gets stuck in the "GO" position, telling cells to multiply uncontrollably, leading to tumors.

For a long time, scientists thought this glitchy KRAS controller was impossible to stop because it didn't have any "off switches" or "handles" that drugs could grab onto. However, this new study found a clever way to disable it by cutting off its power supply.

The Cast of Characters

1. KRAS4A: One of two versions of the glitchy traffic controller. It's the "bad actor" that drives the cancer.
2. DHHC7: A specialized mechanic (an enzyme) that works in the cell. Its job is to apply a specific type of "glue" to KRAS4A.
3. Palmitoylation: The "glue" itself. It's a fatty molecule that sticks to proteins.
4. The Nanocluster: A tiny, high-speed meeting group. When KRAS4A is glued together, it forms these tight little groups on the cell's surface to send strong signals.

The Story: How the Glue Works

1. The Glue is Essential
The researchers discovered that the mechanic DHHC7 applies a fatty "glue" (called palmitoylation) to a specific spot on the KRAS4A controller. Without this glue, KRAS4A is weak and confused. It can't stick properly to the cell's outer wall (the plasma membrane), and even if it does, it can't do its job.

2. The "Party" Analogy (Nanoclustering)
Think of KRAS4A as a person trying to start a conversation.

• Without the glue: KRAS4A is like a shy person standing alone in a huge, empty room. They can't get anyone's attention, so they can't start a conversation (send a signal).
• With the glue: The glue acts like a magnet. It pulls all the KRAS4A controllers together into a tight huddle or a "nanocluster." Now, they are a loud, powerful group. They can easily find their partners (other proteins like RAF) and shout, "Let's grow!"

The study found that this "huddle" is the most important part. It's not just about KRAS4A being on the wall; it's about it being bunched up with its friends.

3. Picking the Right Partners
Interestingly, this glued-up KRAS4A group only talks to specific partners (called ARAF and RAF1). It ignores a third partner named BRAF.

• Analogy: Imagine KRAS4A is a DJ. When it's glued together, it only plays music for a specific dance floor (ARAF/RAF1). If you remove the glue, the DJ stops dancing with that floor and might accidentally start dancing with a different floor (BRAF), which changes the whole vibe of the party. The cancer relies on that specific dance floor to grow.

The Breakthrough: Cutting the Power

The researchers asked: "What happens if we fire the mechanic (DHHC7) so he can't apply the glue?"

• In the Lab: When they removed DHHC7 from cancer cells, the glue disappeared. The KRAS4A controllers couldn't form their "huddles." The signal to grow stopped. The cancer cells stopped multiplying and started dying.
• In Mice: They tested this on mice with pancreatic tumors.
  • Control Group: Mice with normal DHHC7 developed huge, aggressive tumors.
  • Experimental Group: Mice where the DHHC7 mechanic was removed (knocked out) had tumors that simply refused to grow. In some cases, the tumors disappeared entirely.

Why This Matters

This is a big deal for a few reasons:

1. New Target: We can't easily grab the glitchy KRAS controller directly. But we can grab the mechanic (DHHC7) who helps it work. If we stop the mechanic, the controller breaks down.
2. Pancreatic Cancer Hope: Pancreatic cancer is notoriously hard to treat. This study suggests that targeting DHHC7 could be a powerful new weapon against it.
3. Specificity: It seems to work best on the specific version of KRAS (KRAS4A) that drives these cancers, leaving other healthy processes relatively untouched.

The Takeaway

Think of the cancer cell as a car with a stuck accelerator (KRAS). We couldn't figure out how to fix the accelerator itself. But this study found that the accelerator needs a specific type of oil (the glue from DHHC7) to keep the engine running. If we stop the oil from being applied, the car (the cancer) sputters and stops, even though the accelerator is still stuck.

This opens the door for developing new drugs that block the "mechanic" (DHHC7), potentially offering a new way to treat and cure pancreatic and other KRAS-driven cancers.

Technical Summary

1. Problem Statement

• Clinical Challenge: Mutations in KRAS drive nearly 90% of pancreatic ductal adenocarcinomas (PDAC) and ~20% of all human cancers. While recent inhibitors (Sotorasib, Adagrasib) target specific KRAS mutants, they face limitations regarding drug resistance and limited efficacy across the broader spectrum of KRAS-driven cancers.
• Biological Gap: KRAS exists as two splice variants, KRAS4A and KRAS4B. While KRAS4B has traditionally been viewed as the primary oncogenic driver, emerging evidence suggests KRAS4A plays a significant, potentially superior role in driving tumorigenesis via the MAPK pathway.
• Mechanistic Unknown: The specific palmitoyltransferase responsible for S-palmitoylating KRAS4A (at Cys180) was unidentified. Furthermore, the precise mechanism by which this post-translational modification (PTM) regulates KRAS4A signaling—specifically its impact on membrane localization versus nanoclustering and isoform-specific effector activation—remained unclear.

2. Methodology

The authors employed a multi-faceted approach combining biochemistry, cell biology, and in vivo models:

• Screening & Identification: A screen of 24 mammalian DHHC palmitoyltransferases was conducted in HEK293T cells using metabolic labeling with Alk14 and click chemistry to identify enzymes capable of palmitoylating KRAS4A.
• Genetic Manipulation:
  • CRISPR-Cas9: Generated ZDHHC7 (and ZDHHC3) knockout cell lines (HEK293T, MiaPaca-2, AsPC1).
  • siRNA: Knockdown of ZDHHC7 in various pancreatic cancer cell lines.
  • Rescue Experiments: Re-expression of wild-type DHHC7 vs. catalytically inactive DHHS7 in KO cells.
  • Mutagenesis: Creation of KRAS4A mutants (C180S to abolish palmitoylation; G12D for oncogenic activation; G12D/C180S double mutant).
• Biochemical Assays:
  • Acyl-Biotin Exchange (ABE): Quantified endogenous S-palmitoylation levels.
  • In-cell Crosslinking: Used glutaraldehyde to detect KRAS4A nanoclustering (oligomerization) via Western blot.
  • Co-Immunoprecipitation (Co-IP): Assessed interactions between KRAS4A and RAF isoforms (ARAF, BRAF, RAF1).
  • Chemical-Induced Dimerization: Used an FKBP-fusion system with AP20187 to artificially induce clustering in the absence of palmitoylation to isolate the effect of clustering from localization.
• Cellular & In Vivo Models:
  • Soft Agar Assay: Measured anchorage-independent growth in NIH-3T3 cells transformed with KRAS variants.
  • 2D Proliferation: Measured cell viability in pancreatic cancer lines.
  • Xenograft Models: Subcutaneous injection of ZDHHC7 KO vs. Control MiaPaca-2, AsPC1, and PANC0327 cells into NSG mice to assess tumor growth.
• Imaging: Confocal microscopy for membrane localization and Electron Microscopy (EM) with Ripley's K-function analysis for nanocluster quantification.

3. Key Contributions

1. Identification of DHHC7: Identified DHHC7 (ZDHHC7) as the primary palmitoyltransferase responsible for S-palmitoylating KRAS4A at Cys180.
2. Mechanism of Action: Demonstrated that the critical function of KRAS4A palmitoylation is not merely plasma membrane localization (as the C180S mutant retains >50% membrane localization) but rather the promotion of nanoclustering (oligomerization).
3. Isoform-Specific Signaling: Revealed that KRAS4A palmitoylation-driven nanoclustering selectively activates ARAF and RAF1, but not BRAF. This contrasts with KRAS4B, which preferentially activates BRAF.
4. Therapeutic Target Validation: Established that depleting DHHC7 significantly inhibits the growth of mutant KRAS-driven pancreatic tumors in vivo, suggesting DHHC7 as a viable therapeutic target.

4. Key Results

• Palmitoylation and Signaling:
  • Mutation of the palmitoylation site (C180S) in KRAS4A drastically reduced pERK levels.
  • Crucially, this reduction was specific to ARAF and RAF1 phosphorylation; BRAF phosphorylation was unaffected or even relatively enhanced in the absence of palmitoylation.
  • Co-IP confirmed that palmitoylated KRAS4A preferentially binds ARAF/RAF1, while the non-palmitoylated C180S mutant behaves more like KRAS4B (preferring BRAF).
• Nanoclustering is the Driver:
  • The C180S mutation significantly reduced KRAS4A nanoclustering (dimers, trimers, tetramers) as shown by crosslinking and EM.
  • Chemical Rescue: Artificially inducing clustering of the non-palmitoylated KRAS4A G12D/C180S mutant (via FKBP dimerization) restored pERK signaling and ARAF/RAF1 activation, proving that nanoclustering is the direct cause of signaling activation, independent of membrane localization.
• DHHC7 Specificity:
  • ZDHHC7 knockout (but not ZDHHC3) significantly reduced KRAS4A palmitoylation and downstream pERK/pARAF/pRAF1 signaling.
  • Re-introducing catalytically active DHHC7, but not the inactive DHHS7 mutant, rescued these phenotypes.
• Oncogenic Transformation:
  • In soft agar assays, overexpression of DHHC7 enhanced the colony-forming ability of KRAS4A G12D-transformed cells but had no effect on KRAS4A G12D/C180S or KRAS4B G12D.
  • Knockdown of ZDHHC7 reduced colony formation and pERK levels in KRAS4A G12D cells.
• In Vivo Efficacy:
  • Xenografts: ZDHHC7 CRISPR-KO MiaPaca-2 cells (KRAS G12C) failed to form tumors in NSG mice, whereas control cells formed large tumors.
  • Similar significant tumor growth suppression was observed in AsPC1 (G12D) and PANC0327 (G12V) xenografts.
  • In contrast, ZDHHC7 KO in BxPC3 (KRAS Wild Type) showed no significant difference in tumor growth, indicating the dependency on mutant KRAS.
  • Clinical data analysis showed ZDHHC7 is overexpressed in PDAC tumors compared to normal tissue, and high expression correlates with poor patient survival.

5. Significance

• Novel Therapeutic Strategy: This study proposes a new class of therapeutic targets for "undruggable" KRAS cancers: the palmitoyltransferases (specifically DHHC7) that regulate KRAS activity, rather than KRAS itself.
• Mechanistic Insight: It resolves the debate on KRAS4A function, showing that its oncogenic potency relies on S-palmitoylation-mediated nanoclustering to selectively engage the ARAF/RAF1 axis, distinct from the BRAF-centric signaling of KRAS4B.
• Clinical Relevance: The dramatic inhibition of tumor growth in vivo upon ZDHHC7 depletion, even in the presence of mutant KRAS, suggests that targeting DHHC7 could overcome resistance to direct KRAS inhibitors and provide a broad-spectrum treatment for KRAS-mutant pancreatic cancer.
• Hypoxia Connection: The authors note that DHHC7 activity may be enhanced by hypoxia (common in PDAC tumors), potentially explaining why the in vivo effect of DHHC7 depletion is more pronounced than in 2D culture.

In summary, the paper establishes DHHC7 as a critical regulator of KRAS4A oncogenicity via Cys180 palmitoylation, which drives nanoclustering and selective ARAF/RAF1 activation, making it a promising target for pancreatic cancer therapy.